“With Novem, Hyphens can profitably develop the public sector channel for its specialty products to complement its strength in private sector clinics,” says Chew.
PhillipCapital Research analyst Paul Chew has kept a “buy” rating on Hyphens Pharma with an unchanged target price of 43 cents.
Hyphens Pharma’s revenue and patmi for the 1HFY2022 ended June stood at 54% and 67% of Chew’s FY2022 forecast respectively. Earnings were also above the analyst’s expectations due to a then higher-than-expected earnings contribution from the newly acquired Novem and Associates.
